firc institute of molecular oncology

Michael Neuberger

Michael Neuberger

Immunity and DNA deamination, MRC Cambridge

2 November 1953 - 26 October 2013


Prof. Michael Neuberger served as Joint Head of Division of Protein and Nucleic Acid Chemistry at the Medical Research Council Laboratory of Molecular Biology in Cambridge, UK and Honorary Professor of Molecular Immunology at the University of Cambridge.


Prof. Neuberger's major research interests were directed towards understanding the biochemical processes and the physiological pathways by which diversity is created within antibodies.In his 25 years of work on antibodies, he made key discoveries on the molecular mechanisms of antibody gene expression and diversification as well as important contributions to the major technologies underpinning antibody engineering. He published more than 150 manuscripts and is the inventor of several patents and applications in the field of antibody engineering. Up to his last days he served as Member of Scientific Advisory Board at Open Monoclonal Technology, Inc., at AnaptysBio, Inc. (formerly, Anaptys Biosciences, Inc) and at IFOM.

He was also a past or present member of a number of academic and editorial boards and consulted for various companies interested in antibody engineering including Cambridge Antibody Technology (CAT), Xenova-Cantab, and Therapeutic Human Polyclonals.

Neuberger's article

June 2013

A key insight on the enzymatic activity of AID

A commentary to Svend Petersen-Mahrt's paper published on Journal of Experimental Medicine.